跳至主要内容
临床试验/NCT06072508
NCT06072508招募中不适用

Prognostic Interest of Vasorin in Septic Shock

Centre Hospitalier Universitaire, Amiens2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年7月3日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
2
主要终点
correlation between vasorin concentration at day 3 and mortality rate

研究概览

简要总结

In septic shock, the intensity and duration of low blood pressure can lead to a critical reduction in renal tissue perfusion and lead to the onset of more or less severe Acute Kidney Injury (AKI). Vasorin (Vasn) is a protein strongly expressed in large vessels and kidneys, whose functions are still poorly known. Previous experimental studies show that Vasn is associated with decreased Angiotensin II concentrations, a vessel contractility defect and early mortality.

The investigators hypothesize that Vasn (the potential direct regulator of blood pressure) would be an early biomarker predicting the severity of AKI post septic shock, which may be associated with mortality from septic shock or lead to longer-term Chronic Renal Failure (CKD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years old.
  • Hospitalized in intensive care or medical resuscitation units.
  • With a septic shock state defined by 2 mmol/l lactate sepsis, requiring vasopressors to maintain mean blood pressure 65 mmHg (despite adequate vascular filling).
  • Whether or not they have developed AKI.
  • Patient/family information and collection of non opposition

排除标准

  • Patients with chronic respiratory failure.
  • Pregnant women.
  • Patients in palliative care.
  • Information for the patient/someone close and collection of his opposition

结局指标

主要结局

correlation between vasorin concentration at day 3 and mortality rate

时间窗: day 3

correlation between vasorin concentration at day 0 and mortality rate

时间窗: day 0

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Prognostic Interest of Vasorin in Septic Shock | 临床试验